Share the Video:

Psychedelics as The Great Disrupters: Reconstructing the Future of Mental Healthcare

PS2023KetamineMDMAPsilocybinPsychedelic Assisted TherapyPsychedelic ScienceResearch

Ben Sessa

In this upcoming talk and Q&A, Dr. Ben Sessa will discuss how and why different psychedelics such as MDMA, ketamine and psilocybin – all of which have different neurobiological profiles and subjective psychological effects – actually have greater similarities than differences when used in a clinical setting. Underlying these similarities, Ben will describe the traumatic developmental roots of most chronic mental disorders, and will propose that psychedelics, used clinically, are emerging as ‘great disrupters’ of both traditional psychiatric categorical diagnostic systems, and providing a broad base new approach to treating all trauma-based disorders. With nearly two decades in psychedelic research, he will also be exploring the development of psychedelic medicalisation of recent years and some challenges that lie ahead for the newly emerging psychedelics healthcare industry.

Become a MAPS Member with a monthly donation

As a Member, you’re not just making a donation — you’re joining a community that is at the forefront of advancing research, changing policy, and evolving education around psychedelics. Join us in shaping a future where these life-changing tools are available to those who need them most.

Related Videos

PS2023KetamineMDMAPsilocybinPsychedelic Assisted TherapyResearchResources for Therapists

Being a Psychedelic Therapist

Speaker discusses underlying assumptions of psychedelic therapy and therapist's role, emphasizing presence in facilitating healing. Draws from personal experiences with MDMA, psilocybin, and ketamine research volunteers.

Norma Stevens

PS2023AyahuascaIndigenous PeoplePsilocybinPsychedelic Assisted TherapyPsychedelic ScienceResearch

The role of previous experience, gender and set and setting on acute psychedelic experience and its persisting effects

Psychedelic experiences' impact on long-term outcomes in mood and wellbeing varies based on the nature of the experience, set and setting, and individual variables. Data from a psilocybin clinical trial

Tomáš Páleníček

PS2023DepressionHealth ConditionsPsilocybinPsychedelic Assisted TherapyPsychedelic ScienceResearch

Psychedelics and Sexual Functioning: a Mixed-Method Study in Healthy and Depressed Subjects

Psychedelics, historically linked to "free love", show potential for positive impact on sexual feelings. Recent research suggests psilocybin may enhance sexual functioning and satisfaction in healthy and depressed individuals.

Tommaso Barba

PS2023DepressionIntegrationPsilocybinPsychedelic Assisted TherapyPsychedelic ScienceResearch

Psychedelics as relational medicines: Investigating the role of psychosocial factors for outcomes of clinical and naturalistic psychedelic use

Psychedelics are studied for psychiatric disorders; research emphasizes 'set and setting.' Study explores psychosocial factors in psychedelic use, linking communal experiences to improved mental health outcomes.

Hannes Kettner

PS2023DMTLSDMDMAPsilocybinPsychedelic ScienceResearch

A conversation with Amanda Feilding and Rick Doblin, Ph.D.

Amanda Feilding, Founder of the Beckley Foundation, drives the Psychedelic Renaissance with groundbreaking research programs at top institutions worldwide, including pioneering studies on psilocybin, LSD, MDMA, and DMT.

PS2023MDMAPsychedelic Assisted TherapyPsychedelic ScienceResearch

Grounding Psychedelic Research in Memory for Advancing Psychedelic Drug Discovery

M.K.D. discusses how psychedelics impact memory formation, suggesting potential for harnessing plasticity. J.K. concludes on how understanding mnemonic effects can shape clinical use and drug design.

James Keim

PS2023MDMAPolicy and AdvocacyPsychedelic Assisted TherapyPsychedelic SciencePublic BenefitResearch

Preview Scene from Prescription X: The Rick Doblin and MAPS Documentary (Work in Progress)

"Prescription X: The Rick Doblin Story" documents Dr. Rick Doblin's quest with MAPS to legalize MDMA and psychedelics for therapy, culminating in a revealing film by Nirvan and Dream Mullick.

Nirvan Mullick, Dream Mullick

PS2023AyahuascaPsilocybinPsychedelic Assisted TherapyPsychedelic ScienceResearch

Psychedelic Personality Change: Observations, Mechanisms, and Limitations

Four sources of data explore scientific findings on psychedelic-mediated personality change. Results from meta-analytic project, clinical trial, observational findings, and qualitative reports are discussed, along with underlying mechanisms and limitations.

Brandon Weiss

PS2023Health ConditionsPsilocybinPsilocybin-assisted therapyPsychedelic Assisted TherapyPsychedelic ScienceResearch

Family Matters in Psychedelic Therapy: Lessons Learned from a Psilocybin Trial for Anorexia Nervosa

Family involvement in psychedelic therapy can optimize outcomes and prevent problematic patterns. Ethical, neurobiological, and psychological aspects, along with clinical trial data, support the benefits of engaging family members.

Jennifer Danby